RCE Charts, page-1077

You see
separating price action from true valuation can be difficult in small caps with little to no research coverage until they rise to cap levels that fall into broker or investment professional market screens
sometimes after that interest the valuation parameters are so exposed as to create severe price reratings
see rhy for typical example
monetisation expectations were way out for that one even on most conservative parameters - likely still so
sometimes they - ie new bio tech micro caps- “overshoot” short term values vs longer term probable targets
ie nxs par
but gradually return to those levels initially speculated on as time progresses and milestones achieved
very typical to see such price volatility in bio tech with such long timelines to monetisation and regulatory hurdles to overcome - however,
once those get slowly ticked off, the market usually embeds a modest probability to future value and can , as views differ on time to revenue streams, and other wide parameters such as competitive advantage, the market based share price can get quite explosive! Especially as key progress is achieved on milestones concerning bigger pro investor watchers
ie “ we dont usually invest pre phase 2 fda clearance” quote collins st investor group
but they did “break” that rule as expressed publicly in par and its share price i note came up explosive in rerating soon After

i am very confident recce will replicate that profile this year or next
we already know from their in depth long standing research the extraordinary efficacy of their drugs across the total spectrum of bacteria including the worst, most dangerous and penicllin resistant
we know their range of designer drugs work in a unique method of action that cannot be resisted by bacteria ( bactercidal) and far from close to toxic, indeed if at all, at levels of therapy administration requirements well below the possible toxic thresholds - as investigated in the lab against cell cultures
we also know , as a bonus , that recce drugs have been shown to be similarly viruscidal, against corona like virus and in in vitro lab results from several sources including our esteemed csiro , against covid-19
recce has currently multiple fronts of commercial applications with a wide range , and growing designer variants of recce 329, of which any one success many would consider a “company maker”
recce is very well funded to progress right through to phase three trials without investor dilution on capital raises as today’s qtly report shows
many critical trials are currently underway and more on the cusp
lives are likely being saved as i write and one life already documented as likely saved from chronic and likely terminal “unresponsive “ sinusitis - this was thE first in human result under the application of recce 329 on chronic sinus bacterial infection - indeed it had proved resistant to all tried and tested avenues and the prognosis for extension to blood sepsis in the patient from it was not good - in just three days of recce 329 treatment the outcome was published as an outstanding “ miracle” success
thats how potent this novel and unique synthetic designer drug is to heay bacterial infection!
who needs encouraging to invest in this? Maybe the trolls have a different agenda?
ive been in recce now for four years and a major investor
i am so pleased by progress and success i keep buying more on weakness when i can
yes unknown soldier , weep for me, many millions now but only 174 m on issue
so back to the abacus for you